John Fezza, MD
Ophthalmic Plastic and Reconstructive Surgery · Venice, FLNPI 1184715187
Payments from drug & device makers
Across 3,160 payments — averaging $1246.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3.6M
- Merz North America, Inc.$296K
- Visant Medical, Inc.$30K
- Nordic Pharma, Inc.$5K
- Galderma Laboratories, L.p.$4K
- Revance Therapeutics, Inc.$149
- plus $441 from 9 others
Across 2 payments — averaging $11,738 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merz North America, Inc.$23K
What the payments were for
- Royalty or licence$30,0001%
- Consulting fees$1,003,88428%
- Speaking & faculty fees$2,150,92360%
- Travel & lodging$358,13810%
- Food & beverage$62,0492%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 3,076 | $3,602,940 |
| Merz North America, Inc. | 41 | $296,264 |
| Visant Medical, Inc. | 7 | $30,000 |
| Nordic Pharma, Inc. | 1 | $4,999 |
| Galderma Laboratories, L.p. | 20 | $3,777 |
| Revance Therapeutics, Inc. | 1 | $149 |
| Sun Pharmaceutical Industries Inc. | 1 | $125 |
| Amgen | 1 | $119 |
| Oyster Point Pharma, Inc. | 1 | $82 |
| Endo Pharmaceuticals Inc. | 1 | $42 |
| Omeros Corporation | 2 | $38 |
| Boston Scientific | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Arya Medical, Inc. | 4 | $0 |
| Omera Medical, Inc. | 2 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,938,570 in reported general payments places this provider in the 95th percentile of 37 ophthalmic plastic and reconstructive surgery providers in Florida.
See all ophthalmic plastic and reconstructive surgery providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 866 | $7,057 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 95 | $3,439 |
| Tramadol Hcl | 383 | $728 |
| ValacyclovirValacyclovir Hcl | 38 | $552 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 65 | $526 |
| Cephalexin | 38 | $232 |
| Ondansetron OdtOndansetron | 31 | $104 |
| Zolpidem Tartrate | 28 | $69 |
| Tobramycin | 12 | $43 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Venice
- Michael MercandettiVenice$2K
- Sara WesterMiami$1.1M
- Wendy LeeMiami$616K
- Jennifer MurdockMiami$316K
- Ana VictoriaMiami$130K
- Keshini ParbhuWindermere$102K
- Robert ApplebaumLakeland$39K
- Alan LessnerLecanto$19K
- Yasaman MohadjerSt Petersburg$6K
- William MackTampa$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.